Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 871 to 880 of 2733 total matches.
In Brief: A Second Subcutaneous Furosemide Infusor (Lasix ONYU) for Heart Failure
The Medical Letter on Drugs and Therapeutics • Mar 16, 2026 (Issue 1750)
in chronic HF or
chronic kidney disease.1 Furosemide has been available
for years in oral and IV ...
The FDA has approved Lasix ONYU (SQ Innovation),
a subcutaneous formulation of the loop diuretic
furosemide administered via a wearable pump (onbody
infusor), for treatment of edema in adults with
chronic heart failure (HF). A similar product, Furoscix,
is approved for treatment of edema in chronic HF
or chronic kidney disease. Furosemide has been
available for years in oral and IV formulations for
such use.
Med Lett Drugs Ther. 2026 Mar 16;68(1750):47-8 doi:10.58347/tml.2026.1750d | Show Introduction Hide Introduction
In Brief: Two Intranasal Corticosteroid HFA Aerosols for Allergic Rhinitis (online only)
The Medical Letter on Drugs and Therapeutics • Oct 15, 2012 (Issue 1401)
formulations may be better tolerated.
Table 1. Beclomethasone and Ciclesonide for Treatment of Allergic ...
The FDA has approved 2 intranasal HFA (hydrofluoroalkane) aerosols of the corticosteroids beclomethasone dipropionate (Qnasl – Teva Respiratory) and ciclesonide (Zetonna – Sunovion) for once-daily treatment of seasonal and perennial allergic rhinitis. They are the first HFA nasal steroids to become available in the US (HFA propellants do not deplete the ozone layer). Both drugs are already available for these indications as aqueous nasal sprays. Aqueous ("wet") formulations can cause adverse effects such as postnasal drip, moist feeling in the nose, strong odor, and bitter aftertaste,...
Elderberry for Influenza
The Medical Letter on Drugs and Therapeutics • Feb 25, 2019 (Issue 1566)
strains in vitro.1-3 In two small studies
(conducted outside the US), adults with influenza A
or B virus ...
Patients may ask about taking elderberry for prevention
and treatment of influenza. Products containing
elderberry are promoted for relief of cold and flu
symptoms and as an immune system booster.
OTC Differin Epiduo Gel for Acne
The Medical Letter on Drugs and Therapeutics • Jul 20, 2026 (Issue 1759)
gel (Galderma), a fixed-dose combination
of the synthetic retinoid adapalene 0.1% and the oxidizing ...
Differin Epiduo gel (Galderma), a fixed-dose combination of
the synthetic retinoid adapalene 0.1% and the oxidizing agent
benzoyl peroxide 2.5%, is now available over the counter (OTC)
for topical treatment of acne in patients ≥12 years old. It will remain available by prescription for
use in patients 9-11 years old. A gel containing adapalene
0.3% and benzoyl peroxide 2.5% (Epiduo Forte, and generics)
is available by prescription for use in patients ≥12 years old.
Med Lett Drugs Ther. 2026 Jul 20;68(1759):116 doi:10.58347/tml.2026.1759d | Show Introduction Hide Introduction
Drugs for COPD
The Medical Letter on Drugs and Therapeutics • Sep 02, 2024 (Issue 1710)
for Chronic Obstructive Lung
Disease) guidelines for treatment of COPD were
updated recently.1 Treatment ...
The main goals of treatment of chronic obstructive
pulmonary disease (COPD) are to relieve symptoms,
reduce the frequency and severity of exacerbations,
prevent disease progression, and reduce mortality.
GOLD (Global Initiative for Chronic Obstructive Lung
Disease) guidelines for treatment of COPD were
updated recently. Treatment of acute exacerbations
is not discussed here. Drugs available for treatment
of COPD are listed in Tables 1 and 3.
Med Lett Drugs Ther. 2024 Sep 2;66(1710):137-44 doi:10.58347/tml.2024.1710a | Show Introduction Hide Introduction
Drugs for Opioid Use Disorder
The Medical Letter on Drugs and Therapeutics • Sep 04, 2023 (Issue 1684)
,
more than in any previous year.1 Several guidelines on
the management of opioid use disorder ...
Opioid use disorder is a chronic, relapsing disease with
physical and psychiatric components. It is associated
with economic hardship, social isolation, incarceration,
increased rates of blood-borne infections such as HIV
and viral hepatitis, adverse pregnancy outcomes, and
increased mortality. According to the NIH, there were
80,411 deaths involving an opioid in the US in 2021,
more than in any previous year. Several guidelines on
the management of opioid use disorder are available;
all recommend maintenance pharmacotherapy as the
standard of care.
Med Lett Drugs Ther. 2023 Sep 4;65(1684):137-44 doi:10.58347/tml.2023.1684a | Show Introduction Hide Introduction
In Brief: New Warning for OTC Orlistat (Alli)
The Medical Letter on Drugs and Therapeutics • Jul 20, 2026 (Issue 1759)
loss.1 The label
for the 120-mg capsules, which are available by prescription
as Xenical,2 already ...
The FDA now requires a warning about a risk of acute kidney
injury in the product label for the 60-mg capsules of the
pancreatic and gastric lipase inhibitor orlistat, which are
available over the counter as Alli for weight loss.1 The label
for the 120-mg capsules, which are available by prescription
as Xenical, already includes a warning about a risk of
oxalate nephrolithiasis and oxalate nephropathy (orlistat
increases oxalate absorption).
Med Lett Drugs Ther. 2026 Jul 20;68(1759):116 doi:10.58347/tml.2026.1759c | Show Introduction Hide Introduction
Antiviral Drugs for Seasonal Influenza
The Medical Letter on Drugs and Therapeutics • Nov 09, 2026 (Issue 1767)
, and death can
occur, especially in persons at increased risk (see Table 1).
Influenza vaccination reduces ...
Influenza is typically a self-limited illness, but complications
including pneumonia, respiratory failure, and death can
occur, especially in persons at increased risk (see Table 1).
Influenza vaccination reduces the incidence of laboratory-confirmed influenza and the risk of complications associated
with influenza illness. Annual vaccination should be offered
to all persons ≥6 months old as long as influenza viruses are
circulating in the community.
Med Lett Drugs Ther. 2026 Nov 9;68(1767):177-81 doi:10.58347/tml.2026.1767a | Show Introduction Hide Introduction
Teduglutide Injection (Gattex) for Short Bowel Syndrome
The Medical Letter on Drugs and Therapeutics • Apr 15, 2013 (Issue 1414)
and often experience diarrhea, weight loss, malnutrition
and dehydration.1 SBS is the most common diagnosis ...
The FDA has approved teduglutide (te due’ gloo tide;
Gattex – NPS), a recombinant DNA analog of
glucagon-like peptide-2 (GLP-2), for treatment of short
bowel syndrome (SBS) in adults who are dependent
on parenteral support.
Drugs for MRSA Skin and Soft-Tissue Infections
The Medical Letter on Drugs and Therapeutics • May 12, 2014 (Issue 1442)
of the US.1,2 Community-associated MRSA usually
causes furunculosis, purulent cellulitis, and abscesses ...
Methicillin-resistant Staphylococcus aureus (MRSA),
which was traditionally a nosocomially-acquired
organism but now frequently occurs in the absence
of healthcare exposure, is the predominant cause of
suppurative skin and soft-tissue infections in many parts
of the US. Community-associated MRSA usually
causes furunculosis, purulent cellulitis, and abscesses,
but necrotizing fasciitis, necrotizing pneumonia, and
sepsis can also occur.
